Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Antman

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Journal of Hematotherapy|January 1, 1993
The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapyA D Elias, L Ayash, I Tepler, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1994
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by ageK Antman, L Ayash, A Elias, et al.
Cancer|November 1, 1993
The ethical treatment of cancer. What is right for the patient?J Prestifilippo, K Antman, B J Berkman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1985
Selection bias in clinical trialsK Antman, D Amato, W Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984
Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groupsK Antman, H Suit, D Amato, et al.
Cancer Treatment Reports|November 1, 1987
Pharmacokinetics of continuous-infusion high-dose thiotepaW D Henner, T C Shea, E A Furlong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow supportT C Shea, M Flaherty, A Elias, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicityJ E Wright, A Elias, O Tretyakov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancerL J Ayash, C Wheeler, D Fairclough, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantationC Hesdorffer, J Ayello, M Ward, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Journal of Hematotherapy|January 1, 1993
The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapyA D Elias, L Ayash, I Tepler, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1994
High-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy: analysis by ageK Antman, L Ayash, A Elias, et al.
Cancer|November 1, 1993
The ethical treatment of cancer. What is right for the patient?J Prestifilippo, K Antman, B J Berkman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1985
Selection bias in clinical trialsK Antman, D Amato, W Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1984
Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groupsK Antman, H Suit, D Amato, et al.
Cancer Treatment Reports|November 1, 1987
Pharmacokinetics of continuous-infusion high-dose thiotepaW D Henner, T C Shea, E A Furlong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1989
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow supportT C Shea, M Flaherty, A Elias, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1995
High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicityJ E Wright, A Elias, O Tretyakov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancerL J Ayash, C Wheeler, D Fairclough, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 1998
Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantationC Hesdorffer, J Ayello, M Ward, et al.
Pageof 7